rain metastases are the most common intracranial tumors, occurring in up to 40% of cancer patients. 8, 43 Authors recently reported that brain metastases account for approximately 60% of solid metastases arising primarily from lung, breast, kidney, and colon cancer and skin melanoma, causing major morbidity and mortality. 34, 54 In the last decade the incidence of brain metastases has been rising, attributed to the increased survival of cancer patients. Object. Resected brain metastases have a high rate of local recurrence without adjuvant therapy. Adjuvant whole-brain radiotherapy (WBRT) remains the standard of care with a local control rate > 90%. However, WBRT is delivered over 10-15 days, which can delay other therapy and is associated with acute and long-term toxicities. Permanent cesium-131 ( 131 Cs) implants can be used at the time of metastatic resection, thereby avoiding the need for any additional therapy. The authors evaluated the safety, feasibility, and efficacy of a novel therapeutic approach with permanent 131 Cs brachytherapy at the resection for brain metastases. Methods. After institutional review board approval was obtained, 24 patients with a newly diagnosed metastasis to the brain were accrued to a prospective protocol between 2010 and 2012. There were 10 frontal, 7 parietal, 4 cerebellar, 2 occipital, and 1 temporal metastases. Histology included lung cancer (16), breast cancer (2), kidney cancer (2), melanoma (2), colon cancer (1), and cervical cancer (1). Stranded 131 Cs seeds were placed as permanent volume implants. The prescription dose was 80 Gy at a 5-mm depth from the resection cavity surface. Distant metastases were treated with stereotactic radiosurgery (SRS) or WBRT, depending on the number of lesions. The primary end point was local (resection cavity) freedom from progression (FFP). Secondary end points included regional FFP, distant FFP, median survival, overall survival (OS), and toxicity.
I = iodine-125;
131 Cs = cesium-131; FFP = freedom from progression; OS = overall survival; QOL = quality of life; RTOG = Radiation Therapy Oncology Group; SRS = stereotactic radiosurgery; WBRT = whole-brain radiotherapy.
This article contains some figures that are displayed in color on line but in black-and-white in the print edition.
Without treatment, prognosis is dismal with survival of only 1-2 months. However, survival can be extended to 3-6 months with whole-brain radiotherapy (WBRT) and to 11 months with either surgery followed by adjuvant WBRT or surgery plus adjuvant stereotactic radiosurgery (SRS). 19, 20, 29, 45 Although WBRT is effective in preventing local recurrence and controlling distant disease, it has been associated with acute detriments to quality of life (QOL) 10, 32 and deterioration in neurocognitive abilities. 9, 12, 15, 41 In addition, WBRT, as compared with local therapy, offers no overall survival (OS) benefit. 2, 44, 55 For these reasons, attention has turned to the option of aggressive local therapy for oligometastatic disease, deferring salvage WBRT for disease recurrence.
A variety of local postresection treatment strategies are available in this setting. Among such options are postoperative SRS 4, 16, 18, [23] [24] [25] 27, 28, 30, 31, 35, 38, 46, 48, 56 and intraoperative brachytherapy application of either permanent lowdose 7, 13, 22, 51 or temporary high-dose 5, 39, 42, 50, 63 radioisotopes (generally iodine-125 [
125 I]) into the surgical cavity. Postoperative SRS is the more commonly used of these treatment modalities because of its wider availability. Although 125 I has been shown to confer local control comparable to that of postoperative SRS and WBRT, 5, 7, 13, 22, 39, 42, 50, 51, 63 the rates of radiation necrosis have been criticized. A novel radioisotope, 131 Cs confers both physical and radiobiological advantages over postoperative SRS and 125 I brachytherapy. In this prospective study, we evaluated the safety, feasibility, and efficacy of a novel treatment of permanent intraoperative 131 Cs brachytherapy for brain metastases.
Methods

Patient Selection
Between 2010 and 2012, patients with newly diagnosed brain metastases, in whom surgery was deemed appropriate per the inclusion criteria, were accrued to an institutional review board-approved prospective trial and signed informed consent. In general, selection criteria included a metastatic tumor for which surgery was indicated to relieve mass effect, to reduce symptoms, to obtain pathology for diagnostic purposes, or based on a size > 2.5 cm. Patients had to have Eastern Cooperative Oncology Group (ECOG)/Zubrod Performance Status 0, 1, or 2 and expected survival ≥ 6 months. Exclusion criteria included tumor proximity to the chiasm or brainstem (increasing the risk of radiation treatment), small cell carcinoma metastatic to the brain, and pregnancy or unwillingness to practice a form of birth control (abstinence, oral contraceptives, and so forth).
Treatment Approach
Patients underwent maximally safe resection of lesions. The extent of resection and whether surgery was performed en bloc or piecemeal was noted intraoperatively and from postoperative MR images obtained within 48 hours of surgery. At the time of resection, the size of the removed tumor (maximum diameter and volume), its location (supratentorial vs infratentorial), and its relationship to the pia mater (pial vs nonpial) were noted. Also at the time of resection, 131 Cs stranded seeds (IsoRay) with an activity of 3-5 mCi were inserted with a planned dose of 80 Gy to a depth 5 mm from the surface of the resection cavity. The volume implant was precalculated based on preoperative data on tumor size and our institutional physics nomogram and was adjusted real time for the resulting intracavitary volume of the resected metastasis (Fig. 1A) . The 10-cm, suture-stranded 131 Cs seeds (0.5-cm interseed spacing) were delivered in strings of 10 seeds per string, subsequently cut into smaller lengths per the nomogram, and placed as a permanent volume implant along the cavity in a tangential pattern to maintain a 7-to 10-mm spacing between seeds. As a result, the cavity was lined with the seeds in a pattern like barrel staves or parallel tracks (Fig. 1B) . The seeds were then covered with Surgicel (Ethicon) to prevent seed migration and alteration of dosimetry (Fig. 1C) , and Tisseel (Baxter) was used to line the cavity to limit cavity shrinkage and further prevent seed dislodgement (Fig. 1D ). Within 24-48 hours postimplant, the patient underwent CT scanning to determine dose distribution (Fig. 2) .
Follow-Up
Follow-up examination consisted of MRI studies and physical evaluation every 2 months. Magnetic resonance imaging was performed utilizing the following sequences: T1-weighted, FLAIR, T2-weighted, gradient recalled echo, and diffusion-weighted imaging. Moreover, postcontrast Gd-enhanced T1-weighted MR images were obtained in the axial, sagittal, and coronal planes with 3-mm slice thicknesses. Lesion stability on MRI was defined as the absence of new lesions or increased contrast enhancement < 25% in the product of the three perpendicular diameters. Patients were also clinically assessed via physical examination every 2 months with specific attention to any new neurological deficits and symptoms of radiation necrosis, seizures, headaches, personality changes, and motor or sensory deficits, to name a few. The Radiation Therapy Oncology Group (RTOG) scale was used as the radiation toxicity scale. 11 At the time of disease progression, new metastases (distant and regional) were treated with SRS (range 18-20 Gy in one fraction) 1, 2, 53 or WBRT (30 Gy in 10 fractions), [43] [44] [45] depending on the number of lesions.
End Points and Statistical Methods
Descriptive statistics, including the mean, standard deviation, median, range, frequency, and percent, were calculated to characterize the study cohort. Primary end points of the trial were local (resection cavity) freedom from progression (FFP). Secondary end points included regional and distant FFP, median survival, overall survival (OS), and toxicity. Treatment response was rated based on follow-up brain MRI compared with prior MRI. Local FFP was defined as the absence of new nodular contrast enhancement 5 mm or less from the resection cavity. Regional failure was defined as new or increased contrast enhancement more than 5 mm from the resection cavity. Distant failure was defined as new or increased contrast enhancement elsewhere in the brain. All survival end points were defined as the time from the date of resection and implantation of the 131 Cs brachytherapy seeds until 1) the date of local recurrence for local FFP, 2) the date of regional recurrence for regional FFP, 3) the date of new metastasis for distant FFP, or 4) the date of death for OS. Patients without these events were censored at the date of their last follow-up. Kaplan-Meier survival analysis was performed to generate survival curves for the defined survival outcomes. Median and 1-year local FFP, regional FFP, distant FFP, and OS were estimated as appropriate, and 95% confidence intervals were calculated to assess the precision of obtained survival estimates. The Spearman rank correlation coefficient was used to evaluate the correlation between 131 Cs brachytherapy seed characteristics of interest. All p values are 2-sided with statistical significance evaluated at the 0.05 alpha level. All analyses were performed using SPSS version 21.0 (SPSS Inc.) and Stata version 12.0 (StataCorp).
Results
Patient Characteristics
Patient characteristics are summarized in Table 1 . There were 14 females and 10 males with a median age of 65 years (range 45-84 years). Brain metastases were located in the frontal (10), parietal (7), cerebellar (4), occipital (2), and temporal (1) regions. The histology from the metastases was lung (16), breast (2), kidney (2), colon (1), and cervical (1) cancer and melanoma (2) .
Treatment Parameters
Treatment details are shown in Table 2 . Among the 24 patients who underwent resection and 131 Cs brachytherapy implantation, gross-total resection (defined as resection of contrast enhancing disease) was achieved in every case. According to preoperative MRI, the median size of resected tumor was 2.7 cm (range 1.5-5.5 cm), and the median volume of resected tumor was 10.31 cm 3 (range 1.77-87.11 cm 
Patient Survival
At a median follow-up of 19.3 months (range 12.89-29.57 months), 11 patients were still alive and 13 were dead. Table 3 lists the treatment details for each patient. Among the 11 patients who were still alive, 8 had a primary tumor originating in the lung, 2 in the breast, and 1 in the colon. One of these patients had previously undergone SRS for a brain metastasis in a different area and then 131 Cs brachytherapy for a second lesion. Of the 13 patients who died, 8 had a primary tumor originating in the lung, 2 in the kidney, 1 in the cervix, and 2 from melanoma. One of these patients had undergone SRS to a different area of the brain and one had undergone both SRS and WBRT. The median OS was 9.9 months (95% CI 4.8 months, upper limit not estimated; Fig. 3 ). One-year OS was 50.0% (95% CI 29.1%-67.8%).
Freedom From Progression
There were no cases of local recurrence within 5 mm of the resection cavity (Fig. 4) . This yielded a local recurrence FFP of 100%. One patient had a regional recurrence (> 5 mm from the resection cavity), which yielded a 1-year regional FFP of 93.8% (95% CI 63.2%-99.1%; Fig. 5 ). This case was evident 7 months postimplantation * GTR = gross-total resection; STR = subtotal resection.
and was leptomeningeal in origin (Fig. 6 ). This patient was subsequently treated with SRS to a dose of 18 Gy based on RTOG 90-05 53 and was still alive at the time of analysis. Twelve patients had distant metastases, which yielded a median distant FFP of 7.6 months (95% CI 4.1 months, upper limit not estimated) and a 1-year distant FFP of 48.4% (95% CI 26.3%-67.4%; Fig. 7 ). Five patients were treated with subsequent SRS to a different lesion, and three patients were treated with salvage SRS for distant recurrences; all doses ranged from 18 to 20 Gy based on tumor size. 53 Multiple distant brain metastases developed in one patient. She was originally treated with 
Complications
Postoperatively, the patients were treated with 4 mg of dexamethasone twice a day for 2 weeks. There were no instances of radiation necrosis. There was one instance of a dural tear, which required reoperation at 1.2 months postimplantation. Additional complications included one case each of infection and seizure.
Discussion
Resection of brain metastases has been used to establish a histological diagnosis, provide rapid relief of symptoms resulting from the mass effect of a large tumor, and improve local control. Unfortunately, tumor recurrence Fig. 3 . Overall survival. cervix  ---distant  >3  --yes  lung  ---distant  >3  -yes  yes  lung  --yes  ----yes  melanoma  yes  --distant  2  --yes  lung yes
following surgery alone has been as high as 46%. 44 Recurrence rates correlate with factors such as tumor size, location, and histology as well as en bloc resection. With the addition of postoperative radiation therapy, classically in the form of WBRT, the rates of recurrence can be reduced to 10%-20% but at the expense of a good QOL and neurocognitive function. 9, 10, 12, 15, 32, 41, 45 For this reason, attention has turned to the addition of focal radiation, such as postoperative SRS and intraoperative brachytherapy, to the resection bed in an effort to reduce the incidence of local failure.
The use of postoperative SRS to the resected surgical cavity has been increasing, with a number of recent publications. Although a Phase III trial from the North Central Cancer Treatment Group (N107C) comparing postoperative SRS with WBRT in the postoperative setting for brain metastases is in progress, the results of Phase I and II trials demonstrated that local control of the resection cavity with SRS is similar to that with WBRT, ranging from 73% to 94%, with an incidence of radiation necrosis ranging from 0% to 10%. 4 The typical time frame for the delivery of postoperative SRS can be as long as 6 weeks after resection to allow adequate wound healing and the cavity to shrink to a smaller, stable size. The delay in treatment can be disadvantageous, as radiographically evident repopulation of tumor cells has been shown to occur in this time period. 58 Furthermore, the ideal target for SRS is a small round cavity. Tumor cavities of an irregular shape or larger size (> 3 cm) present not only a challenge in developing a treatment plan with a high degree of conformality, but also a potential decrease in local control. Indeed, it has been shown that larger tumor cavities treated with SRS have poor local control as a result of less conformal treatment plans. 1, 17, 37 The actuarial local control rate at 1 year for lesions ≤ 3 cm 3 was 96% (95% CI 90%-100%), and for those > 3 cm 3 was 59% (95% CI 39%-79%). 1 Furthermore, the volume of irradiated tissue is clearly correlated with symptomatic radiation necrosis in patients treated with SRS. 6, 40 Blonigen et al. reported that symptomatic radiation necrosis was observed in 10% and asymptomatic radiation necrosis in 4% of patients who had undergone SRS at a mean dose of 18 Gy. 6 Multivariate regression analysis showed that tumor volume (volume receiving 8 Gy [V8]-V16 Gy) was most predictive of symptomatic radiation necrosis (p < 0.0001). Minniti et al. also reported that following SRS, radiation necrosis occurred in 24% of treated lesions and that as the size of the lesion increases (V12 Gy > 8.5 cm 3 ), there is a greater risk for radiation necrosis. 40 Intraoperative interstitial brachytherapy has several physical and radiobiological advantages for improving local control of resected brain metastases. First of all, intraoperative brachytherapy allows treatment to be delivered at the time of resection, avoiding the time lag apparent in SRS, which allows the tumor cells to repopulate. 58 Unlike SRS, brachytherapy is not limited by the shape or size of the resection cavity, thus allowing homogeneous dose delivery to even irregularly shaped and large surgical cavities. 1, 17, 37 Intraoperative brachytherapy means delivery of the entire treatment (resection plus radiation) in one procedure, which may be more convenient for the patient and may increase patient satisfaction. The ability to deliver all treatment in one setting is particularly appealing for patients who live far from a medical center, for whom travel may be prohibitively expensive and/ or time consuming, especially in a weakened state. Hence, compliance may be increased. Brachytherapy is also more cost effective than WBRT and SRS. 60 Lastly, in contrast to postoperative SRS, which generally requires the application of a metal stereotactic frame affixed with screws to a patient skull, brachytherapy requires no frame or special fixation, as it is performed at the time of surgery.
There are also radiobiological advantages to using brachy therapy. The continuous radiation dose rate of brachy therapy at 0.3-3.5 Gy/hour inhibits mitosis and causes proliferating tumor cells to accumulate in G2, a radiosensitive phase of the cell cycle. 21 There is less radioresistance of hypoxic cells treated with brachytherapy because of impaired repair of sublethal damage under hypoxic conditions 36 and the opportunity for hypoxic cells to become reoxygenated during the treatment. 21 Additionally, brachytherapy allows delivery of a high dose of radiation to a localized area while also providing very steep dose fall-off, thus sparing normal brain tissue outside the vicinity of the tumor bed. 49 Prior studies utilizing intraoperative brachytherapy (most commonly 125 I) have shown local control of the resection cavity between 80% and 95%. 5, 7, 12, 22, 40, 45, 51, 52, 61 Brachytherapy has been used for the treatment of primary brain tumors as well; however, studies have yet to confirm a benefit, and thus standard therapy consists of radiotherapy and chemotherapy or a combination of those depending on the specific histology. 52 Note that criticisms of brachytherapy have focused on the high rates of radiation necrosis, from 0% up to 26% reported in some series. 22 Moreover, the use of permanent brachytherapy seeds leads to the possibility of seed migration, which may impact dose distribution. 57 The use of brachytherapy for local control of newly resected metastases without WBRT has been reported more recently. In these series, radiation necrosis has been more common when using high-dose temporary brachytherapy, such as the GliaSite balloon, with a 23% rate of radiation necrosis. 50 In the permanent continuous low-dose brachytherapy setting, 0% radiation necrosis rates were shown by Bogart et al., who used seeds with an activity of 0.32-0.45 mCi and a cumulative dose of 80-160 Gy using a median of 13 seeds, 7, 47 but achieved a local control rate of only 80%. On the other hand, Huang et al. reported a 26% rate of radiation necrosis using a median of 43 125 I seeds with a median activity of 0.79 mCi and median dose of 800 Gy to the surface (200 Gy to a depth of 1 cm), with a local control rate of 92%. 22 Using these data, Huang et al. concluded that a lower seed activity coupled with a lower prescription dose will probably decrease the rate of radiation necrosis with only a minimal impact on local control.
We carefully took into account the aforementioned information and pitfalls of increased median activity as a direct correlate of an increased risk of radiation necrosis when designing our prospective trial using intraoperative 131 Cs to minimize the incidence of radiation necrosis. The lowered seed activity of 131 Cs and a lowered dose prescription in our study not only achieved a high rate of local control (100%), but also produced no incidence of radiation necrosis. The rationale behind using Another reason for our success may be a more careful, conformal placement of the seeds to prevent areas of inadequate dosing. Complicating the use of interstitial brachytherapy is the gradual shrinkage of the resection cavity, a poorly understood process that progressively moves the seeds closer together over time. 3, 14, 26, 61 However, cavity shrinkage would probably result in pockets of higher dose delivery and higher rates of radiation necrosis, which we did not observe. 33, 62 We undertook several measures to decrease the degree of cavity shrinkage once the seeds were placed. The seeds were not placed as individual seeds but were attached by strings with tensile strength. These strings lined the cavity like barrel staves, maintaining a certain amount of outward pressure on the cavity to keep it from collapsing. Additionally, fibrin glue was placed over the seeds not only to keep them from moving but to create outward pressure on the cavity to prevent cavity shrinkage. Since most of the mass effect of the tumor bulk was relieved after the initial surgery, indicated by the 69.6% shrinkage in cavity volume prior to seed placement, the maintenance of a smaller residual volume during the treatment period did not compromise the surgical goal of relieving mass effect.
Results from the RTOG 90-05 trial have formed the standard of care for recurrent brain metastases treated with single-fraction SRS in the setting of brain metastases previously irradiated with WBRT. 53 Because of the increased risk of radiation necrosis, we concluded that dose depends on tumor volume. In fact, the SRS dose was stratified based on the size of the tumor as follows: 24, 18, and 15 Gy for tumors ≤ 20, 21-30, and 31-40 mm in maximum diameter, respectively. It is interesting to note that these results have formed the basis for prescribed doses in patients without previous radiation as well. The authors reported radiation necrosis rates of 5%, 8%, 9%, and 11% at 6, 12, 18, and 24 months, respectively. However, this included both patients with brain metastases previously treated at a median dose of 30 Gy and patients with primary brain tumors with prior radiation therapy at a median dose of 60 Gy. Therefore, in our study, no dose adjustment was made to account for intraoperative 131 Cs brachytherapy. Another reason for the absence of radiation necrosis in our study is that only one patient proceeded to salvage WBRT. Additionally, our study did not have a considerable amount of large tumors (5 tumors ≤ 20 mm, 12 tumors 21-30 mm, and 7 tumors > 31 mm). Historically, radiotherapy to large tumors has been associated with high rates of radiation necrosis, as seen in RTOG 90-05.
The goal of this novel treatment is to provide a simpler, safer, and more effective method of achieving local control in this patient population. With this treatment modality, there is minimal radiation exposure to family and staff. Additionally, because of the dose fall-off that occurs at 3 feet, patients are not required to have a private room or wear a special lead hat, and family members do not need to be kept at a distance unless they are children or pregnant. At the same time, the method provides the added benefit of delivering two treatments in one procedure and avoids the necessity of numerous visits to the hospital for SRS or WBRT.
Study Limitations
In this analysis, we report results for the initial 24 patients. More substantial numbers of patients from other institutions treated in such a manner will be required to make more definitive conclusions. A multiinstitutional study is underway. Further randomized comparisons between intraoperative brachytherapy and postoperative SRS are indicated. The details of the kinetics and dynamics of the size and shape of the resection cavity and its changes over time will be required for more precise treatment planning, and these studies are ongoing. Finally, formal objective measures of QOL and cognitive processing as well as cost will help in comparing 131 Cs brachytherapy with other treatment options.
Conclusions
This is the first prospective analysis of patients with newly diagnosed metastases treated with maximally safe resection and intraoperative application of 131 Cs. To date, this method of brachytherapy, based on our institutional nomogram and surgical technique, has rendered excellent local control and has proved to be safe and efficacious. A multicenter trial will soon be underway to evaluate this novel radioisotope as a promising modality in the treatment of patients with brain metastases requiring neurosurgical intervention.
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